Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BC Team Leading Innovative Advances for Childhood Cancer Diagnostics

Published: Tuesday, March 18, 2014
Last Updated: Tuesday, March 18, 2014
Bookmark and Share
ChildSeq-RNA assay to identify specific genetic alterations in childhood sarcomas.

A Vancouver based team led by Dr. Poul Sorensen, and funded in part by Genome BC, is providing meaningful advances in identifying genetic alterations in childhood sarcoma cancer tumours.

Childhood sarcomas are aggressive cancers that affect the bones and soft tissues of children and adolescents. These cancers are often very challenging, time-consuming and costly to diagnose accurately using standard microscope and molecular diagnostic techniques (PCR).

Since effective and curative treatments are directly linked to accurate and early diagnosis there is a significant need for precise, rapid and cost-effective molecular tools to help diagnose these cancers. Although, this has been happening with some success more advances are required.

The research team developed a novel diagnostic assay called "ChildSeq-RNA" based on next-generation sequencing technology to identify specific genetic alterations in childhood sarcomas known as gene fusions.

The technology has been proven to be more sophisticated than current methods because it looks for multiple gene fusions at the same time. The assay is also more rapid, informative, and cost-effective than current methodologies.

"This assay has the potential to bring research into real-time clinical analysis," says Dr. Sorensen, Senior Scientist at the BC Cancer Agency and Professor of Pathology and Laboratory Medicine at the University of British Columbia. "In my work I see a genuine need for this kind of diagnostic tool and I am proud that we have come up with it right here in BC."

ChildSeq-RNA is projected to be widely adopted by clinical laboratories worldwide and is being evaluated in a clinical setting at the prestigious and top ranked Texas Children's Hospital at Baylor College of Medicine. The research advances made by the multi-disciplinary team have recently been published in the Journal of Molecular Diagnostics.

"We congratulate the team on the development of this important research and their work to date," said Dr. Alan Winter, President and CEO of Genome BC. "Bringing discovery from bench to bedside is a key tenant of our mission and we are proud to help this team advance a new company based on their technology."

The research project, entitled Use of the Ion Torrent Next Generation Sequencing Platform for Rapid and Accurate Diagnosis of Childhood Cancers was funded through Genome BC's Proof of Concept program which to date represents a total investment of $9.6M for new genomics-related research projects.

This program provides financial support to accelerate the commercialization process for new genomics-related scientific or technological innovations; facilitate the advancement of discoveries based in genomics from the innovation to proof-of-concept stage "in a real world setting"; and develop new and novel products and services to the point that they are ready for licensing, industry investment, or spin-out.

The successful development of the assay has also spurred the creation of Fusion Genomics, a next generation sequencing assay development and bioinformatics company. "In addition to childhood sarcomas, the company is actively pursuing collaborations with leading international institutions to devise new tests for various others cancers, infectious diseases, and other diseases of global importance," says Dr. Mohammad Qadir, Chief Scientific Officer at Fusion Genomics.

"The aim of Fusion Genomics is to offer rapid, unambiguous and cost effective tools, including complete hands off analysis using Fusion Genomics proprietary and secure online computing platform to deliver "benchtop to desktop" services - this could lead to early and more effective diagnosis, which will ultimately save more lives".

Fusion's strategic business development and online computing services, known as a FusionCloud, are being supported through VentureLabs®, a world-class business accelerator program partnership of the University of Victoria, Simon Fraser University, British Columbia Institute of Technology and the Emily Carr University of Art + Design, in collaboration with Compute Canada.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

British Columbia Scientists Link to European Consortium Studying Human Genome
The development of biological resources allow scientists to know how the human genome behaves in health and disease.
Tuesday, May 10, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!